West Africa is often treated as a single region on a slide and as fifteen different regulatory realities in practice. A pharmacovigilance (PV) system that works in one ECOWAS market can fail an inspection in the next, usually for reasons that have little to do with science and a lot to do with local expectations.
Start with what is common
Most authorities in the region are aligned with ICH principles for case reporting and increasingly expect electronic submission in E2B format. A single global safety database, coding in MedDRA and a consistent medical-review process are therefore the right foundation. The mistake is stopping there.
Where the differences bite
- Local responsibility: several authorities expect a named, in-country person responsible for PV, and a defined back-up.
- Reporting channels: national forms, portals and timelines differ, and Francophone markets add language and format expectations.
- Periodic reports and risk management plans: the content you file globally often needs a local annex or adaptation.
- Inspection focus: what an inspector asks to see first varies by authority, so evidence must be easy to retrieve.
Because requirements are updated regularly, confirm the current position with each authority before finalising your plan.
Staffing it sensibly
The temptation is to hire a PV officer per country. A hub-and-spoke model is usually more resilient: a small senior core that owns quality and medical review, supported by local representatives who own relationships and local submissions. It reduces duplicated work and makes inspection preparedness a regional rather than a national exercise.
A PV system scales when what is local is limited to what must be local.
ECP designs and operates regional PV models for pharmaceutical companies across Africa. If you are planning a multi-country rollout, we can help you map obligations and scope the right hub before you commit headcount.
